Gilead was granted FDA approval this week for this latest Hepatitis C medication, Vosevi. The three-part pharmaceutical combines sofsbuvir and velpatasvir in a multi-week regime. The drug has been approved as a second-line defense. Vosevi has already been approved in Europe with a recommendation of an eight-week treatment schedule, though the FDA has omitted this treatment schedule in their approval. Read the full press release here.